Investments in whole genome sequencing and analysis are starting to pay off, with new drugs, diagnostics and disease management strategies, Luke Timmerman writes. Two companies, Adaptive Biotechnologies and Sequenta, are pioneering new approaches to disease diagnosis and management through sequencing that would have been cost-prohibitive several years ago. Studies are under way to determine whether genomics technologies will lower health care costs and improve outcomes, but the personalized medicine payoff is imminent, Timmerman writes.
Genomics investments start to pay off
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||